Background: The intolerance to Acetylsalicylic Acid (ASA) can be detected by conducting oral provocation testing (OPT), which is to gradually introduce low doses of ASA. To perform this test, hospital pharmacies compound small batches of different low-dosage ASA capsules. This work aims to validate a method for fast HPLC-UV assay that allows routine quality control and physicochemical stability studies of capsules. Methods: The chromatographic separation is performed using a C18 column Kinetex (100 A, 50 × 4.6 mm, 2.6 µm) equipped with a precolumn C18. Separation is achieved using a mobile phase composed of water-acetonitrileorthophosphoric acid (68:32:0.2 v/v/v) at a flow rate of 0.8 mL/min and UV detection at 237 nm. Results: Validation shows that the method was suitable for routine analysis and could be used to perform stability studies. Conclusions: The 5, 25, 100 and 250 mg dosed capsules show acceptable stability over 12 months, while the 1 mg dosed capsule show an unacceptable degradation of more than 15 % after 3 months. Therefore, hospital pharmacy can plan the manufacture of capsules and anticipate the requests of doctors.
Introduction
Acetylsalicylic Acid (ASA) is used in medicine since the early twentieth century. It is an anti-inflammatory nonsteroidal drug used at high doses mainly in the symptomatic treatment of slight to moderate pain and inflammation and/or febrile states and at low doses in the prevention of secondary thromboembolic complications in patients with ischemic or artheromateous disease and prevention of thromboembolic events after surgery or vascular intervention [1] . Ferdinand Widal syndrome was described for the first time in 1922. It consists of a triad of symptoms composed of chronic rhinosinusitis with or without nasal polyposis and intolerance to aspirin and/or to other non-steroidal anti-inflammatory drugs [2] . The intolerance to aspirin appears after several years of evolution. It is characterized by the appearance of acute rhinoconjunctivitis with urticaria, associated with significant asthma and potentially leading to angioedema and/or anaphylactic shock. There are no biological test for diagnosing aspirin intolerance [3] . The clinical diagnosis is made following patient questioning and thorough clinical examination, but must always be confirmed by conducting oral provocation testing (OPT). The OPT remains an essential tool to make this diagnosis. OPT aims to gradually introduce very low doses of ASA in a patient suspected of intolerance. Because of its danger, it must be performed within an intensive care unit of a hospital [4, 5] .
Compounding specific low-dosage capsules of ASA has several advantages over diluting existing industrially prepared dosage forms for performing the OPT. First of all, by compounding capsules, there is more control of the administered dose, which allows securing the medical management of the patient. Secondly, it simplifies the preparation and administration of the ASA dose by the medical staff in the service.
However, batch compounding requires qualitative and quantitative controls on routine batch production [6] . Moreover, it is essential to perform stability studies to ensure sufficient expiry dates since these preparations are not used very frequently [7] . Also, as part of the production of capsules content uniformity as it is described in the European Pharmacopeia must be carried out on 10 capsules [6] .
The objective of this work is to validate a method for fast HPLC assay of ASA, for routine quality control of ASA batches produced at different dosages and which can also be used to check the stability of such preparations.
Materials and methods

Chemicals
Chemical reference substances of ASA and salicylic acid (SA) were provided by the European Directorate for the Quality of Medicines and Healthcare (EDQM, France). SA is well known as the degradation product of ASA [8] .
European Pharmacopeia (EP) conforming ASA was provided by Cooper (COOPER, France). HPLC grade purified water was obtained by reverse osmosis and filtration on a Millipore simplicity system (Mercks Millipore, USA) and used to prepare all solutions. Acetonitrile and orthophosphoric acid (≥85 %) were respectively purchased by Sigma Aldrich (Sigma Aldrich, USA) and international VWR (VWR International, France). All chemicals used were of analytical grade.
For the capsule compounding, carmine and lactose were provided by COOPER (Cooper, France) and comply with the requirements of the European Pharmacopoeia. Gelatin capsules provided by Fagron (Fagron, France) were used.
HPLC instrumentation and conditions
A Prominence HPLC system (Shimadzu, Japan) composed of two LC-20AD pumps, an injector Sil-20AC, a CTO-20A oven and a diode array detector SPD-M20A was used and run with the LC-Solution software (Shimadzu, Japan). The chromatographic separation was performed using a C18 column Kinetex (100 A, 50 × 4.6 mm, 2.6 μm) (Phenomenex, USA) equipped with a precolumn C18 (4.6 mm) (Phenomenex, USA) and an in-line filter for UHPLC (Phenomenex, USA). Separation was achieved using a mobile phase (MP) composed of: water-acetonitrile-orthophosphoric acid (68: 32: 0.2, v/v/v) at a flow rate of 0.8 mL/min and UV detection at 237 nm. Column oven temperature was set to 30 ± 5°C, injector at 23 ± 5°C and detector cell at 40°C ± 1°C.
Preparation of stock and standard solutions
Acetylsalicylic acid stock solution (12.5 mg/mL) was prepared in MP and used to prepare 5 standard solutions (0.025, 0.05, 0.075, 0.1 and 0.25 mg/mL). A salicylic acid stock solution (8.15 mg/mL) was also prepared with the MP, and diluted 20 times prior to its injection.
Forced degradation
Forced degradation studies [9] of AAS and capsule of AAS were performed for validate the stability indicating power of the analytical procedure used. A mass of 125 mg AAS or capsule containing 5 mg of AAS were diluted in 10 mL 0.1 HCl or 0.1 NaOH and heat at 60°C for 5 hours. Acid and base treated sample were neutralized and were then diluted to a concentration of 0.125 mg/mL with the mobile phase. The samples were analyzed using HPLC method. The chromatogram obtained from each degradation samples (Figure 2 
Preparation of capsules
Batches of 100 capsules were prepared using a semiautomatic capsule filler with lever lock and stainless steel plate (LGA ® , France). Five different dosages were prepared, 1, 5, 25, 100 and 250 mg. Table 1 summarizes the composition of the different dosed capsules. Lactose monohydrate was used as filler and carmine was used as visual control agent of homogeneity of the mixture. The capsules were packaged in individual opaque blisters ensuring UV protection (Practidose ® France). The blister used ensures an UV protection and is composed of cells that can be detached individually after the labels have been glued. The labels are made of a special paper with an aluminium insulation and an adhesive.
HPLC validation
The analytical validation was performed according to the recommendations of the commission report of SFSTP [10] and NF T90-210 guide lines [11] .
Specificity -degradation products
Specificity was evaluated by injecting a solution of excipients (lactose and carmine) at 5.5 mg/mL in MP.
Forced degradation of 4 solutions presented in § 2.4. was also conducted. These solutions were diluted to 1/3 in the MP before injection.
Linearity
Linearity was checked with MP solutions of ASA alone or ASA mixed with the excipients and repeated five times to ensure reproducibility. ASA concentration ranged between 0.025 and 0.25 mg/mL. Five ASA solutions of different concentrations were prepared from a stock solution to 12.5 mg/mL. Excipient interference was evaluated by using 3 identical powder mixtures as those used to produce the 1, 5 and 25 mg dosed capsules (Table 1) . For these solutions ASA concentrations ranged from 0.05, 0.25 and 0.125 mg/mL.
Robustness
Robustness was evaluated by increase or decrease in flow rate of mobile phase (0.6 mL/min or 1.0 mL/min). The evaluation of this parameter was based on the resolution between the peak of ASA and SA.
Accuracy (reproducibility-repeatability)
Accuracy of the assay has been studied with respect to both repeatability and reproducibility. Accuracy was conducted for 3 mixtures corresponding to 1, 5 and 25 mg/capsule.
For each mixture, 6 samples were prepared and analyzed. This operation was performed 4 more times at the rate of once a day in reproducible conditions by varying one parameter at a time. The varied parameters were: operator, stock solution, column, and day.
Stability of standard solutions
Stability of solutions in the mobile phase (ASA alone or mixed with excipients) was evaluated on the same solutions to the linearity test at different times 0, 4, 8 and 12 hours. They were stored in the automatic injector at 23 ± 5°C. For the stability study, analysis was performed in triplicate, each time using a different stock solution.
Stability study of ASA capsules
The study focused on five dosages 1, 5, 25, 100 and 250 mg. Each dosage assay was conducted on 4 batches, with the exception of the 1 mg dosage for which the study was conducted on 5 batches. The capsules were packaged in individual blister and stored in normal conditions at a 
controlled room temperature (20 ± 5°C). The batches were analyzed at 0, 3, 6, 9 and 12 months using the method of HPLC described above. Content uniformity was based on the European Pharmacopoeia (2.9.40 Uniformity of content of singledose preparations) [12] . For the 1 and 5 mg dosed capsules, the content determination at t 0 requires to individually titrate 10 capsules. For the 25, 100 and 250 mg dosed capsules, content determination was performed by emptying and weighing individually the content of ten capsules. Three samples of 25 mg of powder of the total emptied content was assayed and used for the content determination.
The average concentration expressed in mg/mL was calculated and the percentage of degradation relative to the initial value determined with the following equation:
% of degradation = t x − t 0 t 0 × 100 t x = content determination at time "x" and t 0 = content determination at the beginning of the study. Product stability is demonstrated if the percentage degradation is less than 10 %.
Results
Method validation
Specificity, forced degradation and robustness
In chromatographic conditions, solutions references ASA and SA retention times were respectively 1.32 and 1.74 minutes (Figure 1(a), 1(b) ). Figure 1(c) confirms that the excipients (lactose and carmine) did not interfere with the detection of ASA and its degradation product at 237 nm wavelength. For all solutions tested, forced degradation in acid and alkaline media showed a decrease in the ASA peak and an increase in the SA peak (Figure 2) . Between 0.6 mL/min and 1.0 mL/min, retention times range from 1.8 to 1.09 min for ASA and from 2.53 to 1.52 for SA. The resolution between the two peaks is satisfactory (between 5.12 and 4.8).
Linearity
The assay method of ASA was linear in the tested concentration range (0.025-0.25 mg/mL). The correlation and determination coefficient were respectively: 0.9978 and 0.9957. The results allow the following conclusions through different statistical tests:
-There is a linear relationship between concentration and the detected signal (y = 336.47x + 0.67) -The intercept cannot be equated to 0 (with a risk of 5 %) -The slopes and intercepts were not significantly different between the active ingredient alone and pharmaceutical form reconstituted (with a risk of 5 %, t = 0.5256 and 0.6127).
Accuracy
The relative standard deviation (RSD) for repeatability and reproducibility were determined for each concentration tested (0.05, 0.125 and 0.25 mg/mL). They were all less than 5 %. All data are presented in Table 2 . Any precisions did not exceed the required RSD value (5 %). The maximum value (4.14 %) was observed for worst concentrations. The intermediate precision (repeatability and reproducibility) test was satisfactory. This assay method can be used routinely to control the quality of compounded acetylsalicylic acid capsules as well as a tool to perform stability studies.
Stability of standard solutions in the automatic injector Stability study of ASA capsules Figure 4 shows the evolution of the content of ASA capsules over time. When considering relative degradation, capsules containing 1 mg ASA have a very significant degradation rate of approximately 15 % at 3 months and greater than 30 % at 12 months. For the 5 mg capsules, ASA degradation rate was around 6 % at 12 months. For other doses tested (25, 100 and 250 mg), the degradation rate was less than 5 % at 12 months.
Discussion
For the analytical method, the correlation coefficient was 0.9978, so the method was considered as linear. Moreover, the accuracy, the repeatability and the intermediate precision were systematically inferior to 5 %. So, the method was considered as accurate, repeatable and with an acceptable intermediate precision.
About the stability indicating capacity of the method, for each tested condition (acid hydrolysis and alkaline hydrolysis), the peak of SA, a degradation product of ASA, was observed. The method is thus stability indicating.
The degradation tests have highlighted the ability of the method to detect degradation products of ASA. It can therefore be used to evaluate the stability of the ASA.
About the stability of ASA capsules, when considering absolute quantities of ASA degradation the difference is nearly non-significant suggesting that an equal absolute amount of ASA is degraded due to hydrolysis in capsules. The higher relative degradation for the 1 mg dosed capsule can also be explained by the antioxidant properties of ASA as it is known to act an inhibitor of radical formation and free radical quenching agent [13, 14] . This property is probably responsible for the stability obtained for capsules containing 5 mg and over ASA as it would acts as preservative of itself. But for a content of less than 5 mg, it is too small in regards of the total amount of ASA in the capsule.
Conclusion
This dosage method is to perform quality control and stability studies of compounded ASA capsules containing lactose and carmine. This work is part of a context of small batch production manufactured within hospital pharmacy.
The HPLC-UV method proposed is simple, cheap and quick. It is specific, accurate and precise. It can be used routinely for uniformity testing described in PE. This dosage method has the ability to separate the drug from the degradation product and excipients used in this study. The stability study conducted on the capsules ASA 1, 5, 50, 100 and 250 mg demonstrate that all dosages, except for the 1 mg capsules, are suitably stable for 12 months. Therefore, hospital pharmacy can plan the manufacture of capsules and anticipate the requests of doctors.
It is then possible to respond immediately to this need in case of emergency, as is the case for some patients with imperative cardiologic indications have a history of allergy to ASA. A rapid challenge-desensitization procedure with compounded low-dose capsules of ASA may allow introduction of ASA at therapeutic doses within a few hours [15] .
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